Form 6-K ASTRAZENECA PLC For: Apr 24
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of April 2015
Commission File Number: 001-11960
AstraZeneca PLC
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2015
Results of Annual General Meeting held on 24 April 2015
AstraZeneca PLC announced the results of the voting at its Annual General Meeting today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 12 were passed as special resolutions.
RESOLUTION
|
VOTES FOR
|
% OF VOTES CAST
|
VOTES AGAINST
|
% OF VOTES CAST
|
VOTES CAST IN TOTAL
|
TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL
|
VOTES WITHHELD
|
|
1 |
To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2014 |
877,576,463
|
99.67
|
2,921,581
|
0.33
|
880,498,044
|
69.68%
|
10,675,935
|
2 |
To confirm dividends |
886,527,613
|
99.66
|
2,986,602
|
0.34
|
889,514,215
|
70.40%
|
1,659,763
|
3 |
To re-appoint KPMG LLP, London as Auditor
|
876,751,815
|
98.61
|
12,397,571
|
1.39
|
889,149,386
|
70.37%
|
2,024,593
|
4 |
To authorise the Directors to agree the remuneration of the Auditor |
887,495,062
|
99.82
|
1,629,520
|
0.18
|
889,124,582
|
70.37%
|
2,049,398
|
5a |
To re-elect Leif Johansson as a Director |
851,461,560
|
95.76
|
37,705,142
|
4.24
|
889,166,702
|
70.37%
|
2,007,277
|
5b |
To re-elect Pascal Soriot as a Director |
888,590,119
|
99.95
|
426,241
|
0.05
|
889,016,360
|
70.36%
|
2,157,620
|
5c |
To re-elect Marc Dunoyer as a Director |
885,602,969
|
99.62
|
3,374,856
|
0.38
|
888,977,825
|
70.36%
|
2,196,155
|
5d |
To elect Cori Bargmann as a Director |
888,638,513
|
99.96
|
351,446
|
0.04
|
888,989,959
|
70.36%
|
2,184,021
|
5e |
To re-elect Geneviève Berger as a Director |
888,552,754
|
99.95
|
465,106
|
0.05
|
889,017,860
|
70.36%
|
2,156,120
|
5f |
To re-elect Bruce Burlington as a Director
|
880,639,560
|
99.88
|
1,091,107
|
0.12
|
881,730,667
|
69.78%
|
9,443,312
|
5g
|
To re-elect Ann Cairns as a Director |
888,587,093
|
99.95
|
465,731
|
0.05
|
889,052,824
|
70.36%
|
2,121,156
|
5h |
To re-elect Graham Chipchase as a Director |
876,994,757
|
99.46
|
4,732,631
|
0.54
|
881,727,388
|
69.78%
|
9,445,684
|
5i |
To re-elect Jean-Philippe Courtois as a Director |
880,585,784
|
99.87
|
1,137,760
|
0.13
|
881,723,544
|
69.78%
|
9,450,753
|
5j |
To re-elect Rudy Markham as a Director |
855,335,488
|
99.27
|
6,300,712
|
0.73
|
861,636,200
|
68.19%
|
29,537,348
|
5k |
To re-elect Shriti Vadera as a Director |
888,387,120
|
99.93
|
582,556
|
0.07
|
888,969,676
|
70.36%
|
2,204,192
|
5l |
To re-elect Marcus Wallenberg as a Director |
846,091,821
|
98.19
|
15,599,701
|
1.81
|
861,691,522
|
68.20%
|
29,482,025
|
6 |
To approve the Annual Report on Remuneration for the year ended 31 December 2014 |
739,049,685
|
84.11
|
139,601,566
|
15.89
|
878,651,251
|
69.54%
|
12,522,725
|
7 |
To authorise limited EU political donations |
859,081,444
|
97.36
|
23,307,997
|
2.64
|
882,389,441
|
69.83%
|
8,784,535
|
8 |
To authorise the Directors to allot shares |
808,454,239
|
91.14
|
78,551,101
|
8.86
|
887,005,340
|
70.20%
|
4,168,208
|
9 |
To authorise the Directors to disapply pre-emption rights
|
875,263,416
|
98.61
|
12,347,679
|
1.39
|
887,611,095
|
70.25%
|
3,562,455
|
10 |
To authorise the Company to purchase its own shares |
876,130,644
|
98.54
|
13,023,264
|
1.46
|
889,153,908
|
70.37%
|
2,019,960
|
11 |
To reduce the notice period for general meetings |
778,280,838
|
87.53
|
110,881,255
|
12.47
|
889,162,093
|
70.37%
|
2,011,885
|
12 |
To adopt new Articles of Association |
886,456,629
|
99.90
|
900,552
|
0.10
|
887,357,181
|
70.23%
|
3,813,971
|
Issued capital
As at 22 April 2015, the number of issued shares of the Company was 1,263,544,938, ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
A C N Kemp
Company Secretary
24 April 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
Date: 24 April 2015
|
By: /s/ Adrian Kemp
|
Name: Adrian Kemp
|
|
Title: Company Secretary
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
- IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
- Ridgeline Minerals Announces Upsized Non-Brokered Private Placement to $2.2M
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!